Skip to Main Content


Skip Nav Destination

Abstract CT033: Inducible T cell costimulatory (ICOS) receptor agonist, feladilimab (FE), alone and in combination (combo) with pembrolizumab (PE): Results from INDUCE-1 relapsed/refractory (R/R) melanoma expansion cohorts (EC)

Cancer Res (2021) 81 (13_Supplement): CT033.
This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.
  • Elena Simonetti
  • Serena Cutarella
  • Monica Valente
  • Tommaso Sani
  • Matteo Ravara
  • Michele Maio
  • Anna Maria Di Giacomo
OncoTargets and Therapy (2023) Volume 16: 227.
Close Modal

or Create an Account

Close Modal
Close Modal